CFO of Faeth Therapeutics Buys Nearly 18,000 Shares Amid Surge in Stock, Betting on Next‑Gen CAR‑T Breakthrough
Insider buying surge at Faeth Therapeutics signals strong confidence in its CAR‑T pipeline—CFO’s trust purchases hint at upside potential for value investors.
4 minutes to read